Evaluating antigen targeting and anti-tumor activity of a new anti-cd37 radioimmunoconjugate against non-hodgkin's lymphoma

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 85-96

  Dahle, Jostein ^a   Repetto Llamazares, Ada H V ^a   Mollatt, Camilla S ^b   Melhus, Katrine B ^b   Bruland, Oøyvind S ^c,d   Kolstad, Arne ^d   Larsen, Roy H ^e  

^a Nordic Nanovector AS   (Norway)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e Sciencons Ltd   (Norway)

Author keywords

177Lu; CD37; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; CD37 ANTIGEN; RITUXIMAB; TETULOMAB; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER SURVIVAL; CELL GROWTH; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DAUDI CELL; DRUG BINDING; DRUG DISTRIBUTION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; INTERNALIZATION; MAJOR CLINICAL STUDY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR BIOPSY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LUTETIUM; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; RADIOISOTOPES; TETRASPANINS; TISSUE DISTRIBUTION;

EID: 84873027242     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S and Lewis JP: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16: 3246-3256, 1998.
2. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA and Izon DO: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9: 548-564, 1991.
3. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA and Butchko GM: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329: 459-465, 1993.
4. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P and White CA: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002.
5. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D and Goris M: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23: 712-719, 2005.
6. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS and White CA: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20: 3262-3269, 2002.
7. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ and Kaminski MS: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18: 1316-1323, 2000.
8. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T and Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997.
9. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N and Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445, 1994.
10. Gopal AK, Press OW, Wilbur SM, Maloney DG and Pagel JM: Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112: 830-835, 2008.
11. Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ and Lister TA: Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 114: 881-883, 2001.
12. Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T and Naoe T: Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 390: 48-53, 2009.
13. Wada N, Kohara M, Ogawa H, Sugiyama H, Fukuhara S, Tatsumi Y, Kanamaru A, Hino M, Kanakura Y, Morii E and Aozasa K: Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group. Case Rep Oncol 2: 194-202, 2009.
14. Classon BJ, Williams AF, Willis AC, Seed B and Stamenkovic I: The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OX-44 antigen. J Exp Med 169: 1497-1502, 1989.
15. Schwartz-Albiez R, Dorken B, Hofmann W and Moldenhauer G: The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140: 905-914, 1988.
16. Press OW, Farr AG, Borroz KI, Anderson SK and Martin PJ: Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49: 4906-4912, 1989.
17. Press OW, Howell-Clark J, Anderson S and Bernstein I: Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83: 1390-1397, 1994.
18. Moldenhauer G: CD37. J Biol Regul Homeost Agents 14: 281-283, 2000.
19. Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Kupcu Z, Jacobi A, Muller S, Hirt U, Adolf GR and Borges E: A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118: 4159-4168, 2011.
20. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N and Byrd JC: Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110: 2569-2577, 2007.
21. Smeland E, Funderud S, Ruud E, Kiil BH and Godal T: Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor. Scand J Immunol 21: 205-214, 1985.
22. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW and Vitetta ES: Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer 45: 481-485, 1990.
23. Leblond V, Autran B and Cesbron JY: The SCID mouse mutant: definition and potential use as a model for immune and hematological disorders. Hematol Cell Ther 39: 213-221, 1997.
24. Mitchell P, Lee FT, Hall C, Rigopoulos A, Smyth FE, Hekman AM, van Schijndel GM, Powles R, Brechbiel MW and Scott AM: Targeting primary human Ph(+) B-cell precursor leukemiaengrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies. J Nucl Med 44: 1105-1112, 2003.
25. Fulop GM and Phillips RA: The scid mutation in mice causes a general defect in DNA repair. Nature 347: 479-482, 4-10-1990.
26. Lindmo T and Bunn PA Jr.: Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 121: 678-691, 1986.
27. Dahle J, Krogh C, Melhus KB, Kaalhus O, Larsen RH and Stokke T: A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding. Nucl Med Commun 28: 742-747, 2007.
28. Dahle J, Krogh C, Melhus KB, Borrebaek J, Larsen RH and Kvinnsland Y: In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab. Int J Radiat Oncol Biol Phys 75: 886-895, 2009.
29. Muller WA, Linzner U and Schaffer EH: Organ distribution studies of lutetium-177 in mouse. Int J Nucl Med Biol 5: 29-31, 1978.
30. Brown RS, Kaminski MS, Fisher SJ, Chang AE and Wahl RL: Intratumoral microdistribution of [131I]MB-1 in patients with Bcell lymphoma following radioimmunotherapy. Nucl Med Biol 24: 657-663, 1997.
31. Buchsbaum DJ, Wahl RL, Normolle DP and Kaminski MS: Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 52: 6476-6481, 1992.
32. Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA and Williams DL: Imaging and treatment of B-cell lymphoma. J Nucl Med 31: 1257-1268, 1990.
33. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E and Liu CP: Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10: 1696-1711, 1992.
34. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB and Krohn KA: Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7: 1027-1038, 1989.
35. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D and Porter B: Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329: 1219-1224, 1993.
36. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME and Goldenberg DM: Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 44: 179-188, 1997.
37. Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de JS, Jager PL and de Vries EG: Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 143: 99-106, 2004.
38. Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland OS, Press OW and Larsen RH: Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 110: 2049-2056, 2007.
39. Mitchell P, Lee FT, Hall C, Rigopoulos A, Smyth FE, Hekman AM, van Schijndel GM, Powles R, Brechbiel MW and Scott AM: Targeting primary human Ph(+) B-cell precursor leukemiaengrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies. J Nucl Med 44: 1105-1112, 2003.